Webinar: The use of preclinical human tissue pharmacology assays coupled with ‘omics analysis to better inform precision medicine strategies prior to clinical trials

 The webinar in brief

The webinar describes a study where:

• Diseased tissue ethically acquired from patients suffering from chronic obstructive pulmonary disease (COPD) was used to investigate inter-patient variability in drug efficacy using ex vivo organocultures of fresh lung tissue as the test system.
• The reduction in inflammatory cytokines in the presence of various test drugs was used as the measure of drug efficacy, followed by integration with genotyping information from targeted sequencing data.
• Bioinformatics analysis showed that variants in the CYP2E1 and SMAD3 genes are associated with patient response and may be linked to the observed differences in drug response.

This webinar features data published on the scientific paper available here

Speaker’s biography

Max Bylesjö has been with Fios Genomics since September 2012 and joined the Board of Directors in January 2017. A bioinformatician by training, Max is responsible for the operations group including project delivery. In addition, he oversees the R&D of new analysis methods and the IT infrastructure of the company. Max has a PhD in Chemistry and MSc in Engineering Biology, both from Umeå University, Sweden, and has previous commercial experience from senior positions with Sistemic Scotland and Almac Diagnostics.